ACADIA PHARMACEUTICALS INC
ACADIA PHARMACEUTICALS INC logo

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of central nervous system disorders. The company's lead product, NUPLAZID (pimavanserin), is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Acadia is also developing a number of other potential therapies for the treatment of Alzheimer's disease, schizophrenia, and other CNS disorders.

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.

© 2023-24 DxMultiomics. All rights reserved.